Homoharringtonine, approved for chronic myeloid leukemia, inhibits acute myeloid leukemia growth by targeting the specificity protein 1 (SP1)/TET1 axis and reducing 5hmC levels. The gene discussed is SP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.